Models
1
Deploy Watch
Track CMR Surgical on Deploy.
We notify you when a verified state change lands on the record, not when the company issues a claim.
Key facts
Product
Gating events
wikidata
wikipedia
Founded
Key product
FDA clearance
Data & sources
Press releases
2
News coverage
1
Web sources
1
4 sources backing this record.View all →
Models (1)
View all models →CMR Surgical on the deployment map
Where CMR Surgical's robots are verified operating. Explore the deployment map by place and type.
Relationships
Explainers
Plain-language answers to the questions people ask about CMR Surgical, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.
- What is a surgical robot?
A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.
- What is CMR Versius?
CMR Versius is a modular soft-tissue surgical robotic system from CMR Surgical, a UK-based company founded in 2014. Per DEPLOY's surgical cluster framework: international commercial soft-tissue surgical archetype with established commercial deployment volume across EU + UK + Australia + India; US FDA clearance state operates at cap-flag posture pending primary-source confirmation of submission status. Editorial distinction: modular architecture (separate cart-mounted instrument arms) structurally distinct from Intuitive da Vinci monolithic design (single patient-side cart). Three editorial axes within one entity: international commercial soft-tissue surgical archetype + modular-architecture distinction from Intuitive's monolithic design + non-US market state. Cohort positioning: international commercial soft-tissue surgical archetype within the surgical cluster, extending the cluster's structural axes from FDA-clearance-posture (Wave 1) into clinical-domain + commercial-model variance.
Current leadership (5)
- Massimiliano Colella CEOIR-verified
- Mark Slack Co-founder & Chief Medical OfficerIR-verified
- Luke Hares Co-founder & Chief Innovation OfficerIR-verified
- Luke Hares Chief Innovation Officer & Co-founderreported, not verified
- Martin Frost Co-founder & former CEOreported, not verified
Founders (3)
- Mark Slackcofounderfounded 2014-01-01
- Luke Harescofounderfounded 2014-01-01
- Martin Frostcofounderno longer at company
Safety record
3 incidents on record (1 serious, 2 minor). Most recent: Apr 2026.
Most recent: Apr 2026
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Incidents affecting CMR Surgical (3)
- CMR Surgical Versius Plus receives FDA 510(k) clearance for gallbladder surgery2026-03-15 · Regulatory action
- FDA clears CMR Surgical Versius Plus surgical robotic platform for cholecystectomy (510(k))2025-12-17 · Regulatory action
Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.
Recent coverage
CMR Surgical in third-party press
Peer companies
- Johnson & Johnson3 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
- Stryker2 models
Supplied by (1)
Compute / semiconductor
- NVIDIAvia VersiusNVIDIA IGX Thor industrial AI compute platform -- adopted as early-adopter evaluation for next-generation Versius surgical robotic system; IGX Thor delivers up to 5,581 FP4 TFLOPS AI compute with 400 GBe connectivity for real-time surgical AI inference and decision support; CMR Surgical also contributed anonymized surgical data to NVIDIA Isaac GRooT-H vision-language-action model for healthcare roboticssuppliesannounced
Inbound supply edges feeding this company directly or via the models it owns. Same source bar as the outbound view (verified against at least two strong sources).
Financial state
- Reporting basis
- private_reported
- Lifecycle stage
- growth
- Counterparty risk class
- moderate
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Partnerships (1)
- CMR Surgical x NVIDIA Surgical Robot Training with NVIDIAtechnology
Funding rounds (2)
- Series D2021-06-01
$600M(reported)
Investors: SoftBank Vision Fund 2 (lead)
- Series C2019-09-01
$240M(reported)
Investors: SoftBank Vision Fund 1 (lead)
Regulatory filings (2)
- fda_de_novofda de novo · us_fdacleared2024-10-01
Linked models: Versius
- DEN230078fda de novo · us_fdagranted2023-11-21reported
Linked models: Versius
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Verified media addedVerifiedJun 5, 2026
CMR Versius Plus
- Verified media addedVerifiedJun 5, 2026
Versius robotic cholecystectomy
- Verified media addedVerifiedJun 4, 2026
Introducing Versius
- Record createdJun 3, 2026
Added to the verified registry
- Incident recordedApr 7, 2026
CMR Surgical Versius: hand-controller arm went still and console became unrecoverable,...
Sources (4)
- https://www.globenewswire.com/news-release/2024/10/15/cmr-surgical-versius-fda-de-novo
- https://www.therobotreport.com/cmr-surgical-receives-fda-clearance-for-versius-plus-surgical-robot/
- https://www.massdevice.com/cmr-surgical-200-million-funding/
- https://www.globenewswire.com/news-release/2026/03/17/cmr-surgical-nvidia-igx-thor
Common questions
- What is CMR Surgical?
- UK surgical-robotics company (Cambridge; founded 2014) making the Versius modular multi-arm teleoperated surgical robot; FDA De Novo 2024 + Versius Plus 510(k) 2025; >40k procedures ex-US.
- What does CMR Surgical make?
- CMR Surgical has 1 robot model on the DEPLOY registry: Versius (CMR Surgical builds both physical robots and the AI that runs them).
- Is CMR Surgical publicly traded?
- No. CMR Surgical is privately held and not publicly traded, per the DEPLOY registry.
- Who competes with CMR Surgical?
- On the DEPLOY registry, peer companies to CMR Surgical building in the same form factors include Johnson & Johnson, Intuitive Surgical, LEM Surgical, MicroPort MedBot.
- Who is the CEO of CMR Surgical?
- Massimiliano Colella is the ceo of CMR Surgical, per the DEPLOY registry.
- How can I invest in CMR Surgical?
- CMR Surgical is a private company; its shares are not available on public markets, so retail investors cannot buy the stock today.
- Where is CMR Surgical headquartered?
- CMR Surgical is headquartered in Cambridge, United Kingdom.
- Who owns CMR Surgical?
- CMR Surgical is privately held; ownership sits with its founders and private investors.
- Where does CMR Surgical operate robots?
- CMR Surgical is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.
- Is CMR Surgical a top robotics company?
- On DEPLOY's intelligence score, which blends verified deployments, funding, hiring, media, safety, and IP signals, CMR Surgical ranks in roughly the top 46% of companies tracked by the registry.
- Are there any incidents involving CMR Surgical?
- 3 active incidents involving CMR Surgical are on the DEPLOY registry. Each is a sourced, append-only record; retracted incidents are suppressed from this view.
- Is CMR Surgical safe?
- CMR Surgical has 3 active incidents on record in the DEPLOY registry. 3 incidents on record (1 serious, 2 minor). Most recent: Apr 2026. Retracted incidents are excluded from this count.
Methodology: Claimed (not regulatorily cleared) · 4 sources (2 primary) · last reviewed 2026-07-08
Verification posture
Claimed (not regulatorily cleared)
Cap-flag required
Review state
Drift-flagged
Last reviewed 2026-07-08
1 anchored drift pattern(s); see cap_flags
Sources by quality tier
- 2
- primary-company-ir
- Company IR disclosure
- 1
- secondary-trade-publication
- Trade publication
- 1
- unclassified
- Unclassified source
Cap flags
Claim: CMR Surgical Versius is fully US-pending FDA
Honest status: Versius has De Novo authorization (October 2024, cholecystectomy) and Versius Plus 510(k) clearance (December 2025). Only gynecology 510(k) is currently pending. The wholesale-pending framing is aggregator drift.
Versius is partially US-cleared: De Novo Oct 2024 (cholecystectomy) + Versius Plus 510(k) Dec 2025. Only gynecology 510(k) currently pending.
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for CMR Surgical.Peer companies
- Johnson & Johnson3 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
- Stryker2 models
In the press
Recent coverage mentioning CMR Surgical from third-party publications. Automatically surfaced; not part of the verified registry record.
CMR Surgical secures 510k clearance of Versius Plus robotic surgical system
CMR Surgical received FDA 510k clearance for its second-generation Versius Plus surgical robot for cholecystectomy procedures, paving the way for US commercial launch in 2026.…
FDA Clears New Robotic Platform for Gallbladder Surgery
CMR Surgicals Versius Plus received FDA 510(k) clearance for gallbladder surgery, on track for US commercialization in 2026.
CMR Raises 00M in Series D Funding for Versius Surgical Robots
CMR Surgical raised 00M in Series D funding to scale Versius, its minimally invasive surgical robot system.
Machine-readable surfaces
- Markdown mirror: /companies/cmr-surgical.md
- RSS feed: /companies/cmr-surgical/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/6bbb447e-0278-4ae1-822d-8b546420511e
- Revision history: /companies/cmr-surgical/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- Johnson & Johnson3 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
- Stryker2 models
Video
Transforming Surgery. For Good. The Versius® Surgical Robotic System is CE marked according to EC Directive 93/42/EEC (the MDD) and is intended to assist in th
Our Chief Medical Officer, Mark Slack on how Versius is transforming surgery. Transforming Surgery. For Good. cmrsurgical.com Connect with us: Twitter: http
► Subscribe to Our Channel Here https://www.youtube.com/MullingsGroup --------------- LinkedIn: http://www.linkedin.com/company/the-m... Website: http:/
Watch Professor David Jayne, Consultant Colorectal Surgeon at Leeds General Infirmary provide an insight to the Versius surgical robotic system and its applicat
Experience the live demonstration at Arab Health 2023, an extraordinary event presented by Robotics Surgical Systems! Join us as we showcase the future of surgi
Luke Hares, the visionary behind the Versius surgical robotic system, talks about the key to the Versius design - the human arm - and how Versius' unique design
John Acker (CMR Surgical) discusses advances in the new laparoscopic robotic surgery platform - CMR Surgical. Talk given at the 1st annual symposium for the Hou
What if access to robotic surgery was no longer limited by space, cost or constraints? Versius Plus™ is designed to move with you - unlocking access to the pati
Reality vs attention
CMR Surgical draws attention at the 62nd percentile but verifies reality at the 55th percentile among surgical robots. Hype Gap +6.5, 12th widest among surgical robots.
6-month trend
Analysis
Safety profile within acceptable range for category. Deployment footprint remains limited relative to category peers.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Jul 18, 2026